Kaken Pharmaceutical Co., Ltd. (4521) Operating Income 2023–2026

Name: Kaken Pharmaceutical Co., Ltd. (4521) operating income history 2023-2026
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-08-11

Kaken Pharmaceutical Co., Ltd. annual operating income for fiscal 2026 was -JPY 897 million, compared with JPY 21.0 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

4521 Annual Operating Income

Operating Income (annual)	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Operating Income (EBIT)	(JPY 897M)	JPY 21.0B	JPY 9.5B	JPY 8.0B

JPY; JPYM / JPYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Operating Income at Comparable Companies

3692 Operating Income — Hansoh Pharmaceutical Group Company Limited
4887 Operating Income — Sawai Group Holdings Co., Ltd.
4553 Operating Income — Towa Pharmaceutical Co., Ltd.
4547 Operating Income — Kissei Pharmaceutical Co., Ltd.

More 4521 metrics: Revenue · Gross Profit · Net Income · EPS · Free Cash Flow

All 4521 financial statements → Interactive 4521 charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.